In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.

Saved in:
Bibliographic Details
Title: In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels.
Authors: Cherry JJ; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., DiDonato CJ; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America., Androphy EJ; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Calo A; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Potter K; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America., Custer SK; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Du S; Precision Medicine, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Foley TL; Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.; Primary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America., Gopalsamy A; Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Reedich EJ; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.; Human Molecular Genetics Program, Ann & Robert Lurie Children's Hospital, Stanley Manne Research Institute, Chicago, Illinois, United States of America., Gordo SM; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Gordon W; Precision Medicine, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Hosea N; Pharmacokinetics and Drug Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Jones LH; Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Krizay DK; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., LaRosa G; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Li H; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Mathur S; Business Technology, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Menard CA; Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America.; Primary Pharmacology Group, Pfizer Worldwide Research and Development, Groton, Connecticut, United States of America., Patel P; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Ramos-Zayas R; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Rietz A; Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America., Rong H; Pharmacokinetics and Drug Metabolism, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Zhang B; Clinical Genetics, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America., Tones MA; Rare Disease Research Unit, Pfizer Worldwide Research and Development, Cambridge, Massachusetts, United States of America.
Source: PloS one [PLoS One] 2017 Sep 25; Vol. 12 (9), pp. e0185079. Date of Electronic Publication: 2017 Sep 25 (Print Publication: 2017).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1932-6203
DOI:10.1371/journal.pone.0185079